Oregon Public Employees Retirement Fund Takes $482,000 Position in Amneal Pharmaceuticals, Inc. $AMRX

Posted by Geri Gentry on Jul 15th, 2026

Oregon Public Employees Retirement Fund purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 38,800 shares of the company’s stock, valued at approximately $482,000.

Several other institutional investors have also added to or reduced their stakes in AMRX. Spire Wealth Management grew its holdings in Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after buying an additional 1,023 shares in the last quarter. Intech Investment Management LLC increased its position in Amneal Pharmaceuticals by 1.2% during the 4th quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after buying an additional 1,159 shares during the period. Hsbc Holdings PLC increased its position in Amneal Pharmaceuticals by 1.6% during the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after acquiring an additional 1,569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Amneal Pharmaceuticals by 2.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after purchasing an additional 1,582 shares in the last quarter. Finally, Comerica Bank raised its stake in Amneal Pharmaceuticals by 56.1% in the 4th quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after purchasing an additional 1,685 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Trading Down 2.9%

Shares of NASDAQ:AMRX opened at $16.69 on Wednesday. The firm has a 50 day moving average of $14.80 and a 200-day moving average of $13.80. The stock has a market capitalization of $5.32 billion, a PE ratio of 43.92 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a 12 month low of $7.66 and a 12 month high of $17.86.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The business had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. On average, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 17.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

AMRX has been the topic of a number of analyst reports. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Barclays lifted their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, UBS Group initiated coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.80.

Check Out Our Latest Research Report on AMRX

Amneal Pharmaceuticals Profile

(Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.